SAN DIEGO - illiNews -- Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and development contract for $16.5 million with options for an additional $30.0 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) to advance MBP091 though the completion of a Phase 1 clinical trial.
MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo.
Marburg virus is a member of the filovirus family and causes a hemorrhagic fever similar to that caused by Ebola. First identified in 1967, Marburg virus has caused numerous outbreaks, even as recently as 2017 in Uganda, with relatively high mortality rates. "The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus," said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this contract.
More on illi News
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Chief Executive Officer.
###
About Mapp Biopharmaceutical: Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a National Institute of Health grant No. 2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.
MBP091 is a single human monoclonal antibody (mAb) that is being developed as a pan-Marburg virus therapeutic for the treatment of hemorrhagic fevers caused by Marburg and the closely related Ravn virus. The mAb was isolated in the laboratory of Dr. James Crowe at Vanderbilt University Medical Center from a survivor or Marburg virus infection and subsequently licensed by Mapp. MBP091 has been evaluated in numerous preclinical experiments and has demonstrated the ability to neutralize Marburg virus in vitro and protect from lethal challenge of Marburg in vivo.
Marburg virus is a member of the filovirus family and causes a hemorrhagic fever similar to that caused by Ebola. First identified in 1967, Marburg virus has caused numerous outbreaks, even as recently as 2017 in Uganda, with relatively high mortality rates. "The award of this contract by BARDA will allow Mapp to advance the development of MBP091 to first in human evaluation with the ultimate goal of making this medical countermeasure available to victims of Marburg virus," said Dr. Ronald Aimes, Vice President of Nonclinical Development at Mapp and the Principal Investigator on this contract.
More on illi News
- Annual MSP 501 Identifies Best-in-Class Global MSP Businesses & Leading Trends in Managed Services
- Pvilion Awarded $1.5 Million USAF Phase II SBIR Contract for Autonomously Deployable Structures
- U.S. Army Awards DiSTI $10M Delivery Order for JLTV Trainers
- VORAGO Technologies announces family expansion and size reduction of radiation-hardened Arm® Cortex® MCUs into BGA packages for Defense and Aerospace
- Aircraft Sensors Market worth $4.4 billion by 2025 - Exclusive Report by MarketsandMarkets™
"We are pleased to continue and expand our productive relationship with BARDA, which represents a good example of a public-private partnership that advances much needed therapeutics for infected individuals and the Strategic National Stockpile," said Dr. Kevin J. Whaley, Chief Executive Officer.
###
About Mapp Biopharmaceutical: Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. www.mappbio.com
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201900018C and HHSO100201700023C, a National Institute of Health grant No. 2SB1 AI082744 and Medical CBRN Defense Consortium Base Agreement 2018-843 under OTA W15QKN-16-9-1002.
Source: Mapp Biopharmaceutical, Inc.
Filed Under: Medical, Government
0 Comments
Latest on illi News
- Maccabi USA Men's Basketball Announces New Head Coach For 21st Maccabiah
- Genuine Hospitality, LLC Selected to Operate the New Home2 Suites by Hilton-Chicago/O'Hare International Airport
- Chicago: Mayor Lightfoot Joins Governor Pritzker and Blue Cross and Blue Shield of Illinois (BCBSIL) for Ribbon Cutting on New South Side Facility
- Naperville: Municipal Election Petitions for Candidacy Available Monday, Aug. 17
- Clarity Gold Reported 2.32 oz/t Au - Sent Crews to Three High Grade Gold Properties in BC
- Doctor Develops Personalized Solution to COVID-19 Threat
- Immunohistochemistry/IHC Market worth $2.7 billion by 2025 - Exclusive Report by MarketsandMarkets™
- Andrew Carnegie Global Capital Announces a $20M Fintech Venture with Braintree in the Coming Year
- Andrew Carnegie Global Capital Has Announced an Equity Investment in a Brantstone Properties Development Project – London, Slated 2023
- What if Bon Jovi's Drummer Had Been an Indian Temple Musician From 800AD?
- New Memoir By U.S. Marine: Releasing on Amazon September 06 2020
- Building Your Success System. Unique New eBook
- Onlive Server Announced Europe based Germany VPS Server Hosting Services with KVM Hypervisor Cloud Panel
- South Side Food Co-op Sponsors C.O.R.E. Songwriting Competition, 2020
- ICON Jewel's Famed Hollywood Jeweler Talks Diamonds, Covid And These Uncertain Times
- Why We Need More Black Executives in Hip Hop? by Eric B
- City Of Chicago Launches 'Your Home Is Someone's Workplace' – A Campaign To Support All Care Workers
- 360Quadrants Releases Quadrant of Best Data Acquisition System Providers in 2020
- Marshals Of The Revolution-New Roots Country Music and Lifestyle Brand Has Arrived
- Avoiding the 17a-4 Quagmire - AdvisorVault's Guide for Small FINRA Firms